New Treatments for Advanced Thyroid Cancer

The webcast activity "New Treatments for Advanced Thyroid Cancer" was orignially presented at CEU 2015, the Endocrine Society's 67th Clinical Endocrinology Update Meeting, held in Miami, FL on September 12, 2015.

Expert faculty discusses the evolving therapeutic landscape in the management of advanced thyroid cancer with an emphasis on recent trial updates.

The activity was supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc. and Eisai Inc.

 

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, and healthcare professionals who treat patients with thyroid disorders

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Summarize the mechanism of action of recent MKIs in the treatment of RAI-refractory DTC
  • Recognize MKI indications and contra-indications in the application of therapy
  • Identify patients with thyroid cancer most likely to benefit from MKI therapy
  • Discuss recent updates in clinical data on efficacy of recently approved MKIs

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Systems-based Practice
Topic Area: 
Quality Improvement and Healthcare Delivery
Hormones and Cancer
Thyroid/HPT Axis
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation
Course opens: 
10/01/2015
Course expires: 
10/31/2016
Rating: 
0
Intercontinental Miami Hotel
Miami, FL
United States

Lori J. Wirth, MD
Assistant Professor of Medicine, Harvard Medical School
Medical Director, Center for Head and Neck Cancers
Massachusetts General Hospital
Boston, Massachusetts

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Lori J. Wirth, MD: Speaker, Ashion, Eisai, Loxo

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships: Larry Fox, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation

Accreditation Period

Course opens: 
10/01/2015
Course expires: 
10/31/2016